Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar hadar resistant to tigecycline

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1319-1322

  Hentschke, M ^a   Christner, M ^a   Sobottka, I ^a   Aepfelbacher, M ^a   Rohde, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CHLORAMPHENICOL; CIPROFLOXACIN; MINOCYCLINE; RAMR PROTEIN; TET A PROTEIN; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ESCHERICHIA COLI; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALMONELLA ENTERICA; WILD TYPE;

ANTI-BACTERIAL AGENTS; ANTIPORTERS; BACTERIAL PROTEINS; DNA TRANSPOSABLE ELEMENTS; DRUG RESISTANCE, BACTERIAL; GENETIC VARIATION; HUMANS; MINOCYCLINE; MUTATION; REPRESSOR PROTEINS; SALMONELLA ENTERICA;

EID: 77149164413     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00993-09     Document Type: Article

References (31)

1. Abouzeed, Y. M., S. Baucheron, and A. Cloeckaert. 2008. ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 52:2428-2434.
2. Aminov, R. I., J. C. Chee-Sanford, N. Garrigues, B. Teferedegne, I. J. Krapac, B. A. White, and R. I. Mackie. 2002. Development, validation, and application of PCR primers for detection of tetracycline efflux genes of gram-negative bacteria. Appl. Environ. Microbiol. 68:1786-1793.
3. Bratu, S., D. Landman, A. George, J. Salvani, and J. Quale. 2009. Correlation of the expression of acrB and the regulatory genes marA, soxS and ramA with antimicrobial resistance in clinical isolates of Klebsiella pneumoniae endemic to New York City. J. Antimicrob. Chemother. 64:278-283.
4. Chopra, I., and M. Roberts. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol. Mol. Biol. Rev. 65:232-260.
5. Clinical Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. M7-A7. Clinical Laboratory Standards Institute, Wayne, PA.
6. Clinical Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. M100-S18. Clinical Laboratory Standards Institute, Wayne, PA.
7. Damier-Piolle, L., S. Magnet, S. Bremont, T. Lambert, and P. Courvalin. 2008. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob. Agents Chemother. 52:557-562.
8. Dean, C. R., M. A. Visalli, S. J. Projan, P. E. Sum, and P. A. Bradford. 2003. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 47:972-978.
9. Fluit, A. C., A. Florijn, J. Verhoef, and D. Milatovic. 2005. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob. Agents Chemother. 49:1636-1638.
10. Guay, G. G., M. Tuckman, and D. M. Rothstein. 1994. Mutations in the tetA(B) gene that cause a change in substrate specificity of the tetracycline efflux pump. Antimicrob. Agents Chemother. 38:857-860.
11. Hirata, T., A. Saito, K. Nishino, N. Tamura, and A. Yamaguchi. 2004. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob. Agents Chemother. 48:2179-2184.
12. Keeney, D., A. Ruzin, and P. A. Bradford. 2007. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb. Drug Resist. 13:1-6.
13. Keeney, D., A. Ruzin, F. McAleese, E. Murphy, and P. A. Bradford. 2008. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J. Antimicrob. Chemother. 61:46-53.
14. Kelesidis, T., D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas. 2008. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 62:895-904.
15. McAleese, F., P. Petersen, A. Ruzin, P. M. Dunman, E. Murphy, S. J. Projan, and P. A. Bradford. 2005. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob. Agents Chemother. 49:1865-1871.
16. O'Regan, E., T. Quinn, J. M. Pages, M. McCusker, L. Piddock, and S. Fanning. 2009. Multiple regulatory pathways associated with high-level ciprofloxacin and multidrug resistance in Salmonella enterica serovar Enteritidis: involvement of ramA and other global regulators. Antimicrob. Agents Chemother. 53:1080-1087.
17. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
18. Peterson, L. R. 2008. A review of tigecycline: the first glycylcycline. Int. J. Antimicrob. Agents 32(Suppl. 4):S215-S222.
19. Piddock, L. J. 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19:382-402.
20. Poole, K. 2005. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56:20-51.
21. Reid, G. E., S. A. Grim, C. A. Aldeza, W. M. Janda, and N. M. Clark. 2007. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27:1198-1201.
22. Ricci, V., and L. J. Piddock. 2009. Ciprofloxacin selects for multidrug resistance in Salmonella enterica serovar Typhimurium mediated by at least two different pathways. J. Antimicrob. Chemother. 63:909-916.
23. Ruzin, A., F. W. Immermann, and P. A. Bradford. 2008. Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 52:3430-3432.
24. Ruzin, A., D. Keeney, and P. A. Bradford. 2005. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob. Agents Chemother. 49:791-793.
25. Ruzin, A., D. Keeney, and P. A. Bradford. 2007. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J. Antimicrob. Chemother. 59:1001-1004.
26. Ruzin, A., M. A. Visalli, D. Keeney, and P. A. Bradford. 2005. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 49:1017-1022.
27. Stein, G. E., and W. A. Craig. 2006. Tigecycline: a critical analysis. Clin. Infect. Dis. 43:518-524.
28. Tuckman, M., P. J. Petersen, A. Y. Howe, M. Orlowski, S. Mullen, K. Chan, P. A. Bradford, and C. H. Jones. 2007. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline. Antimicrob. Agents Chemother. 51:3205-3211.
29. Tuckman, M., P. J. Petersen, and S. J. Projan. 2000. Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb. Drug Resist. 6:277-282.
30. Visalli, M. A., E. Murphy, S. J. Projan, and P. A. Bradford. 2003. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. 47:665-669.
31. Werner, G., S. Gfrorer, C. Fleige, W. Witte, and I. Klare. 2008. Tigecyclineresistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J. Antimicrob. Chemother. 61:1182-1183.